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High grade gliomas (HGG) including glioblastomas (GBM) are the most common and devastating primary brain tumours.
Despite important progresses in GBM treatment that currently includes surgery combined to radio- and chemotherapy, GBM
patients’ prognosis remains very poor. Immunotherapy is one of the new promising therapeutic approaches that can specifically
target tumour cells. Such an approach could also maintain long term antitumour responses without inducing neurologic defects.
Since the past 25 years, adoptive and active immunotherapies using lymphokine-activated killer cells, cytotoxic T cells, tumour-
infiltrating lymphocytes, autologous tumour cells, and dendritic cells have been tested in phase I/II clinical trials with HGG
patients. This paper inventories these cellular immunotherapeutic strategies and discusses their eﬃcacy, limits, and future
perspectives for optimizing the treatment to achieve clinical benefits for GBM patients.
1. Introduction
Glioblastoma is the most common primary brain tumour in
humans [1] and has the most severe prognosis [2, 3]. Despite
improved surgical management and a multimodal treatment
of concomitant radiotherapy and chemotherapy, followed by
adjuvant chemotherapy with temozolomide (TMZ) [4], the
prognosis remains poor with median survival of less than 15
months. Research has thus actively focused on testing new
therapeutic approaches, including immunotherapy.
Until recently, it was generally assumed that immune
reactions do not occur in the brain because of the blood-
brain barrier (BBB) and the specific features of the brain such
as the absence of conventional lymphatic vessels or the low
level of circulating T cells. It is now known however that the
central nervous systemmaintains a two-way communication
network with the immune system. Infectious or experimental
autoimmune encephalomyelitis animal models allow better
understanding of how the immune system operates in the
brain.
Under physiological conditions, the brain contains sev-
eral diﬀerent immune cell populations. Microglial cells,
which most likely arise from hematopoietic cells, colonize
the central nervous system during embryonic development
and come to account for 5 to 20% of cells in the central
nervous system.Macrophages and dendritic cells (DC) which
arise from monocytes circulating in the blood stream are
found in perivascular zones, the choroid plexuses, and
the meninges. Microglial cells constitute the first line of
defense for the brain. They migrate toward inflammatory
zones and, after activation, possess phagocytic properties
and synthesize several types of cytokines and chemokines
enabling the recruitment of other immune cells [5]. Adaptive
immune reactions are initiated in cervical nodes. The T cells
activated in these nodes present a particular phenotype with
an overexpression of α4/β7 integrins and therefore exhibit
tropism for the brain [6]. At the present time, the way in
which antigens are transported from the brain to the cervical
nodes remains unclear. It has been shown in animal models
of brain tumours that antigen presenting cells (APC) exit
in the brain parenchyma by migrating along the external
capsule to reach the cervical nodes [7]; the drainage system
is nevertheless diﬀerent in rodents and humans. In humans,
it is known that brain antigens reach the cervical nodes [8],
although whether they arrive associated with APC or not
remains to be elucidated.
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Due to the complex cellular organisation of brain capil-
lary vessels composed of endothelial cells with tight junctions
and associated pericytic and astrocytic cells [9, 10], the BBB
contributes to the selective entry of immune cells from the
periphery into the brain parenchyma. In particular, the mul-
tistepmodel of ”rolling/activation/adhesion/transmigration”
through the endothelial wall has been proposed to control
the arrival of activated T cells into the brain [9, 10].
This mechanism is finely regulated by multiple molecular
interactions involving adhesion molecules (i.e α4/β7 inte-
grins) and chemokines such as CXCR3 [9, 10]. However, in
GBM patients, the BBB appears to be disorganised with a
asymmetric structure of brain capillaries into the tumour,
a dysfunction of tight junctions between endothelial cells,
and a decrease in BBB-associated pericytes [9, 11, 12]. In this
context, rules that control the traﬃcking of eﬀector T cells
into the tumour site might be completely diﬀerent.
Diﬀerent models have been proposed to better under-
stand the eﬀector phase of the immune response in the
brain. For example, following a nasal infection with a
herpes simplex virus, the first observation is the arrival of
macrophages and a few neutrophils, then a few NK and
T cells, which will become predominant [13]. Lymphocyte
migration was followed in a recent study with injections
of CD4+ lymphocytes directed against myelin proteins
in a model of autoimmune encephalitis: after arriving in
the subarachnoid spaces (in leptomeningeal vessels), the
lymphocytes migrated along the internal wall of the vessels.
After diapedesis, they migrated along the external walls and
if they encountered APC (macrophages or DC) presenting
myelin antigens, they were then reactivated, synthesized
numerous cytokines, and penetrated the brain parenchyma
[14]. The brain environment plays a key role for the local
expansion of CD8+ lymphocytes. In a glioma mouse model,
after they arrived to the brain, CD8+ T cells can proliferate
and further diﬀerentiate with enhanced IFNγ and granzyme
B expression. These conditioned CD8+ T cells express αEβ7
integrins which enhance their retention into the brain [15].
This induced expression of αEβ7 integrins could be due to
the presence of TGFβ. In an infection model, a secondary
expansion of CD8+ T cells into the brain was observed and
was due to the presence of DC in situ [16].
An adaptive immune response implies antigen recogni-
tion. Our team has demonstrated, in a series of 47GBM, the
frequent overexpression of four tumour antigens: IL13Rα2,
EGFRvIII, gp100, and TRP2 [17], which are known to induce
immune reactions. Other antigens associated with GBM
have been described including EphA2, survivin, WT1, SOX2,
SOX11, MAGE1, AIM2, and SART1 [18]. T cells directed
against IL13Rα2 and EphA2 have been demonstrated in
the peripheral blood mononuclear cells (PBMCs) of a long
surviving patient with anaplastic astrocytoma, showing that
a spontaneous immune reaction can occur in HGG [19].
While T-cell infiltration is not observed in the normal
brain, it can be observed in glioma. Mittelbronn et al. used
an immunohistochemistry technique to demonstrate CD8
expression in a few cells (less than 0.1% of the total cell mass)
in a series of GBM [20]. In four GBM, Barcia et al. found
that CD8+ T cells are preferentially located in the brain
parenchyma and in proximity to vessels while CD4+ T cells
(less numerous than CD8+ cells in 3 of the 4 cases) are not
found in the parenchyma. In addition, these lymphocytes can
express granzyme and form synapses with tumour cells. A
few granzyme-expressing NK cells were also found [21]. In
the latest contribution, another team used flow cytometry
to demonstrate that 0.1 to 3.2% of cells found in tumour
tissues express CD3. Half of these cells also express CD56
and are for the majority CD4+. However, these unusual
CD4+ CD56+ cells, preferentially found in GBM, do not
express CD1d or Vα24 TCR chains that are typical markers
for NKT cells [22]. Overall, these results suggest that immune
reactions are occurring in primary brain tumours, but are
largely ineﬀective as shown by the inevitable recurrence of
the disease.
There could be two ways of using immunotherapy for
brain tumours. The first is the “active immunotherapy”
designed to boost the patient’s native immune response.
The second is the “passive immunotherapy” where in vitro
activated immune cells or specificmolecules (e.g. antibodies)
directly targeting tumour cells are injected. This paper is
focused on immunotherapy trials based on cell therapy,
exclusively published until may 2010 and inventoried in
MEDLINE accessed by the NCBI Pubmed database. All trials
with GBM patients (included trials with GBM and other
HGG) were selected.
2. Adoptive Immunotherapy
In adoptive immunotherapy, immune cells activated ex
vivo are administrated to the tumour-bearing patient. The
activated cells are either injected directly into the tumour
cavity or intravenously. The first types of cells used for
gliomas were lymphocyte-activated killer (LAK) cells [23–
34]. LAK cells are generally obtained by cultivating periph-
eral lymphocytes in the presence of IL2 (±lectins) yielding
populations with diﬀerent sets of T cells and NK cells with
cytolytic properties not specifically directed against tumour
cells. Cytotoxic T lymphocytes (CTL) can also be used. CTL
can be generated by ex vivo antigenic stimulation of PBMC.
For gliomas, autologous tumour cells (ATC) are generally
used as antigen source [35–37]. Allogeneic CTL stimulated
by the patient’s own lymphocytes have also been tested
[38]. After amplification in the presence of IL2, CTL can
be obtained from tumour infiltrating lymphocytes (TIL), as
was done in one study [39]. Another approach was to collect
lymphocytes from lymph nodes or PBMC after peripheral
injection of irradiated ATC and GM-CSF, stimulating them
in vitro then reinjecting them [40–44].
2.1. Adoptive Immunotherapy Using LAK. Twelve trials treat-
ing HGG with LAK have been reported in the literature
(Table 1). One pilot study [28], six phase I trials [23–26, 29,
31], and five phase I/II trials [27, 30, 32–34], including 211
patients. In all of these studies except one, the patients were
included when their disease relapsed. LAKwere administered
intracerebrally and delivered into the operative cavity or
directly into the lesion. Intrathecal administration was used
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in one patient. Number of injected cells ranged from 1× 106
to 1 × 1010 LAK, generally associated with IL2 doses to the
order of 109 units per injection. One to fifteen injections were
given per patient.
Neurological toxicity was observed in six of the nine trials
reporting this factor. The patients presented brain edema
or symptoms of aseptic meningitis. Hypereosinophilia was
detected in the cerebrospinal fluid or in the peripheral blood
in two patients [37] and infiltrations of mononuclears and
eosinophils were found in nine of the eleven reoperations
and in all three autopsies a regional eosinophilia being
associated with increased survival [30, 32].
To assess the eﬃcacy of the treatment, most of the
published trials reported in this paper used radiological
response criteria: partial response (PR) defined as more
than 50% radiographic reduction in tumour volume; minor
response (MR) defined as 50 to 25% reduction; and stable
disease (SD) defined as less than 25% reduction or less
than 20% progression of tumour volume; finally, progressive
disease (PD) defined as more than 20% progression in
tumour volume or a new lesion. Radiological response
reachedMR at least once in nine of the twelve trials reporting
the radiological response. Combining all reports in the
literature, there were 5 CR (complete response) (3GBM),
13 PR (8GBM), and 6 SD (6GBM) in a total of 118 patients.
Correlation between the clinical results and radiological
response has not been significant [27].
In some trials, median survival for vaccinated GBM
patients was higher than the one observed for control
groups [30, 32, 33]. For the only trial on newly diagnosed
GBM, median overall survival (OS) was 20.5 months, with
75% of patients alive at one year. In this study, a positive
correlation was demonstrated between the number of LAK
injected and survival as well as a negative correlation between
corticosteroid therapy and survival [34].
2.2. Adoptive Immunotherapy Using Other Cell Types. Five
trials testing adoptive immunotherapy for HGG have used
CTL obtained from PBMC or TIL in 30 patients (Table 2).
These were four phase I trials using CTL [35–38] and one
pilot study using TIL [39]. In all five trials, the immune
cells were injected intracerebrally. Three other phase I
trials [40–42] and two pilot studies [43, 44] used CTLs
obtained from lymph nodes or PBMCs after intradermal
vaccination in a combination strategy using both active and
adoptive immunotherapy in 65 patients. The immune cells
were injected intravenously, or associated with intracarotid
infusion.
In the ten published studies, the number of injections
ranged from 1 to 13. The number of cells injected varied from
3 × 107 to 10 × 1010. IL-2 injections were associated in four
trials. Delayed type hypersensitivity (DTH) was observed
in reaction to the tumour cells at the point of injection in
three of the five trials associating vaccination with adoptive
therapy.
Tolerance was satisfactory in all the published trials
with no reported grade III/IV events, even with intravenous
injections.
Clinically, the ten published trials have reported at least
a few cases of SD (n = 18) as well as 28 PR and 3 CR
among 95 patients treated. Four studies have even been able
to demonstrate a benefit in survival. One study failed to find
any PR but reported disease-free survival ≥ 8 months in 7 of
15 patients treated, including one patient with > 40 months
survival [40]. In one trial, there was a correlation between
clinical response and the predominant CD8+ phenotype of
T cells present into the vaccines [43]. A correlation between
clinical response and immune response revealed by DTH
response to autologous tumours was also observed [43, 44].
In the pilot study using autologous TIL, the cytotoxic
activity of the vaccines tested in vitro against autologous
tumours varies depending to the patients and was not
correlated to the clinical outcome [39]. However, it is
interesting to note that the only patient with CR contained
a distinct population of CD8+CD56+ cells (around 20%).
As TIL obtained from other patients with PR, TIL exhibited
cytotoxic activity against K562 cells, a typical target for NK
cells. In contrast, TIL from the patient that failed to respond
to the treatment showed no activity against these cells. One
could speculate that the presence of cells with NK activity
could help the TIL anti-tumour responses [39].
Adoptive immunotherapy leads to clinical responses in
some HGG patients: Objective responses have been observed
with the minimal number of 3 × 108 LAK cells and 107
CTL injected intracerebrally. The absence of clear correlation
between the number of eﬀector cells, their cytotoxic activity
against autologous tumours, and the clinical outcome might
be due to the large variability observed between patients
and the limited number of patients enrolled in these trials.
This renders diﬃcult, if not impossible, to define an optimal
scheme of treatment based on published clinical trials using
adoptive immunotherapy. Injection of CTLs or TIL appeared
however to allow higher objective responses compared to
LAK. Using a mathematical model, Kronik et al. have
predicted that GBM would be eradicated by intensive doses
from 3 × 108 to 2 × 109 alloreactive CTL injected every
4 to 5 days, dependent of the size of the tumour burden
[45]. The impact of chemotherapy or corticosteroids on
the treatments’ eﬃcacy is also controversial. Whereas these
drugs were completely avoided in some trials because of their
immunosuppressive eﬀects [23, 31, 33, 34], others studies
have shown no influence of steroids or chemotherapy on
the generation and the lytic activity of the eﬀector cells
[24, 26, 27]. Remarkably, the eosinophil infiltration at the
tumour site and in CSF is described in several clinical trials
using LAK and CTL [30, 32, 38, 39]. This might be linked
to the use of IL2 or GM-CSF, known to induce systemic
hypereosinophilia. However, the involvement of these cells in
the anti-tumour response should be addressed.
3. Active Immunotherapy
Several antigen sources can be used for active immunother-
apy such as intact tumour cells, tumour protein lysates,
tumour-derived mRNA, peptides eluded from tumourMHC
class I molecules, and synthetic peptides. Antigens can be
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Table 1: Adoptive immunotherapy in high-grade gliomas using lymphokine activated killer (LAK) cells∗.
References
Type of
trial
Patients Administration Clinical responses
[23] Phase I
N = 6 progressive
HGG
IC (1 injection) No PR or SD
[24] Phase I
N = 13 recurrent
GBM
IC (2 injections)
1 SD
No survival benefit
[25] Phase I
N = 9 recurrent
HGG 7GBM and
2AA
IC (15 injections)
1 PR (AA)
No survival benefit
[26] Phase I
N = 20 recurrent
HGG
11 evaluated:
9GBM/2AA
IC (1 to 2 injections)
Median survival after IT: 18
weeks (>90 weeks—N = 2)
Median OS: 63 weeks
Correlation between
survival and the number of
LAK injected
[27] Phase I/II
N = 19 recurrent
gliomas
14GBM/5 GIII
IC (2nd injection if
survival >4 months)
2 PR (GIII)
2 PR, one after 2nd
injection (GBM)
Median survival after IT: 30
weeks
No correlation between
clinical and radiographic
responses
[28] Pilot study
N = 5 recurrent
GBM
IC (1 injection)
No PR or SD
No survival benefit
[29] Phase I
N = 9 recurrent
GBM
IC
1 CR, 2 PR, 4 SD
Median OS: 18 months
[30] Phase I/II
N = 19 recurrent
HGG
15 GBM, 4AA
IC (2 injections) 2nd
cycle if no PD
1CR (AA),
1 delayed CR, 2 PR, 1SD
(GBM)
Median survival after IT: 53
versus 25.5 weeks (GBM)
[31] Phase I
N = 10 recurrent
malignant tumours
4GBM, 2 AIII-IV,
2 AII-III, 1 AOA, 1
MDB
IC (N = 9)Intrathecal
(N = 1 MDB)(4 to 5
injections)
2 PR (AII-III)
Median survival after IT: 13
weeks Median OS: 78 weeks
[32] Phase I/II
N = 28 recurrent
HGG
IC (2 injections) 2nd
cycle if no PD
1 CR (AA)
1 CR, 2 PR (GBM)
Median OS: 53 versus 26
weeks (GBM)
[33] Phase I/II
N = 40 recurrent
GBM
IC (1 injection)
Median survival after IT: 9
months (excluded
secondary GBM)
Median OS 17.5 versus 13.6
months (excluded
secondary GBM)
[34] Phase I/II
N = 33 newly
diagnosed
GBM post RT+CT
IC (1 injection)
Median OS: 20.5 months
Correlation between
survival and the number of
LAK injected; Correlation
between survival and
absence of corticoids before
treatment
∗: Abbreviations used in this table: AII/III: grade II and III astrocytoma; AIII/IV: grade III and IV astrocytoma; AA: anaplastic astrocytoma; AO: anaplastic
oligodendroglioma; AOA: anaplastic oligoastrocytoma; CR: complete response; CT: chemotherapy; GII/III: grade II and III glioma; GIII/IV: grade III and
IV glioma; GBM: glioblastoma; HGG: high-grade glioma; IC: intracranial injection; IT: immunotherapy; MDB: medulloblastoma; OS: overall survival; PR:
partial response; RT: radiotherapy; SD: stable disease.
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Table 2: Adoptive immunotherapy in high-grade gliomas using cytotoxic T lymphocytes (CTL) or tumour-infiltrated lymphocytes (TIL)∗.
References Type of trial Patients Administration Immune response Clinical responses
CTL obtained from PBMC
[35] Phase I
N = 5 HGG
2 newly
diagnosed
GBM,
2 recurrent
GBM, 1AOA
IC (7 to 13
injections)
2 PR (1GBM, 1AOA)
No survival benefit
(survival >2 years—
N = 1AOA)
[36] Phase I
N = 4 HGG
3GBM, 1AA
IC (3 injections) 3 PR (1AA), 1 SD
[37] Phase I
N = 10
recurrent HGG
7GBM, 2AA,
1 AOA
IC (3 injections)
1 CR (AA), 4 PR (3GBM, 1
AA), 3 SD (GBM)
Median survival: > 5
months
[38] Phase I
N = 5
recurrent HGG
2GBM, 1AA, 2
AO
IC (3 to 11
injections)
Cerebrospinal fluid
hypereosinophilia
3 SD (1 AA, 2 AO) No
survival benefit
CTL obtained by lymphocytes from draining lymph nodes or PBMC after vaccination with irradiated ATC
[40] Phase I
N = 15
recurrent HGG
12GBM, 3AA
IV (1 to 3
injections)
DTH (15/15)
No PR or SD
Free disease survival: ≥ 8
months (N = 7) (>40
months N = 1)
[41] Phase I
N = 10
recurrent HGG
9GBM, 1AA
IV (1 injection)
3 PR (1AA, 2GBM)
Survival after reoperation:
> 1 year (N = 4/8)
[42] Pilot study
N = 9 recurrent
HGG
6 GBM, 3 GIII
IV +/−
intracarotid
infusion (1
injection)
DTH (9/9)
3 PR (1GBM, 2 GIII with
survival > 4 years)
Correlation between clinical
response and CD4/CD8
composition of infused cells.
[43] Phase I
N = 12 newly
diagnosed
glioma: 6 GBM,
2GII, 4 GIII
IV (1 to 2
injections)
4 PR (2GBM, 2GIII)
2 SD (2GII)
[44] Pilot study
N = 19
recurrent HGG
16GBM, 2AA,
1 gliosarcoma
IV (1 injection) DTH (17/19)
1 CR, 7 PR, 9 SD
Median survival: 12
months Correlation between
survival and DTH response
Autologous TIL
[39] Pilot study
N = 6HGG 3
GBM, 3 AA
IC (2 injections)
1 CR (AA), 2 PR (1AA,
1GBM)
∗: Abbreviations used in this table: see Table 1; DTH: delayed-type hypersensitivity; PBMC: peripheral blood mononuclear cells; IV: intravenous.
used alone and injected in the presence of diﬀerent adjuvants
or presented on DCs which play a key role in initiating the
immune reaction.
3.1. Active Immunotherapy Using ATC. Vaccines based on
ATC have been used for HGG in eight studies (Table 3) [46–
53]: five pilot studies of antitumour vaccination [47, 48, 50–
52], one phase I trial [53] and reported in two cases report
[46, 49] for a total of 71 treated patients. ATCs are generally
inactivated by radiation, sometimes genetically modified [46,
49, 51], and can be infected with a virus [47, 50] to boost
the induced immune reaction. In one case, the cells harvested
after surgery were treated with antisense oligonucleotides for
insulin growth factor receptor 1 (IGF-IR/AS ODN) before
implantation [48]. One pilot study used ATC collected from
a fixed tissue, which enabled inclusion of a greater number of
patients [52]. Indeed, the establishment of primary lines is a
limiting factor; the lack of enough tissue can retard the first
vaccination after surgery.
The cells were administered subcutaneously in six series,
and intradermally in two others. Injections were associated
in two studies with IL2 [47] or GM-CSF infusions [49].
The number of cells injected varied from 106 to 1011. The
vaccination was repeated in all of these studies, generally for
three cycles with a total of 1 to 13 injections.
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Table 3: Active immunotherapy in high-grade gliomas using autologous tumour cells (ATC)∗.
References
Type of
trial
Patients
Antigen source
Immune
activation
Administration
Immune
response
Clinical responses
[46]
Case
report
N = 1 recurrent
GBM
irradiated ATC
+ fibroblasts
genetically
modified to
secrete IL 2
SC (10 injections)
ATR PBMC
(lytic activity)
No survival benefit at 4
months
[47] Pilot study
N = 11 newly
diagnosed
GBM after
surgery and RT
ATC infected
with NDV and
inactivated with
cisplatinum
SC (4 to 5
injections)
DTH
(11/11-infected
ATC)DTH
(3/11-ATC) TI
CD4/CD8 T
cells (4/4)
No survival benefit
No correlation between
survival and DTH response
[48] Pilot study
N = 12
progressive
HGG
8 GBM, 4 AA
ATC +
IGF-IR/AS
ODN
SC (1 to 10
injections)
TI lymphocytes
(4/9)
1 CR 2 PR 2 SD (GBM)
1 CR, 2 PR (AA)
[49]
Case
report
N = 1 recurrent
GBM
irradiated ATC
+ fibroblasts
genetically
modified to
secrete IL 4
ID (2 injections in
5 sites)
No ATR PBL
(ELISPOT)
1 PR-survival: 10 months
[50] Pilot study
N = 23 GBM
after RT
irradiated ATC
infected with
NDV
ID (5 to 8
injections)
DTH (15/15)
ATR PBMC
(3/3) (IFNγ
ELISPOT)
TI CD8 cells
(6/7)
1 CR
Median OS: 100 versus 49
weeks
[51] Pilot study
N = 6
3 recurrent
GBM
3 melanoma
irradiated ATC
transduced with
B7-2 and
GM-CSF
SC (3 injections)
No ATR
PBMC(CTL
activity) (GBM)
Longer free disease survival
(3/6–1 GBM)
[52] Pilot study
N = 12GBM
8 newly
diagnosed GBM
4 recurrent
GBM
formalin-fixed
ATC tuberculin
microparticles
as adjuvant
SC (3 injections in
5 sites)
DTH (9/12)
1 CR, 1 PR, 2 MR, 1 SD
Median survival: 10.7
months 3 of 5 responders
survival > 20 months
[53] Phase I
N = 5 recurrent
HGG
4GBM, 1AOA
irradiated ATC SC (4 injections ) DTH (2/5) 3 SD (GBM)
∗: Abbreviations used in this table: see Table 1 and Table 2; ATR: anti-tumour responses; ID: intradermal injection; IGF-IR/ASODN: insulin-like growth factor
type I receptor antisense oligodeoxynucleotide; MR: minor response; NDV: Newcastle-Disease-Virus; PBL: peripheral blood lymphocytes; SC: subcutaneous;
TI: tumour infiltration.
Tolerance was acceptable in all trials, without any grade
III/IV toxic events. There were only a few cases of fever,
erythema, and perturbed liver tests. Preventive measures
for thromboembolism had to be associated with IGF-IR/AS
ODN administration [48].
In most studies reported, at least some patients exhibited
immune response induction either in periphery (DTH
against the injected tumour cells or anti-tumour responses
of PBMC) or most importantly at the tumour site. CD8 T
cell infiltration was found for example in one study in six out
of seven patients who underwent a reoperation for relapse,
but was not found in the four control patients who had a
reoperation [50].
The clinical response was evaluated radiologically in five
studies demonstrating 4CR (3GBM), 6 PR (4GBM), 2MR
(2GBM), and 6 SD (6GBM) in a total of 53 patients.
Three patients with SD in the study of Clavreul et al.
appeared to have a longer than usual survival (42, 62, 88
weeks) after a second surgery without other treatment [53].
In this particular study, GM-CSF was infused continuously
or discontinvously at the site of the ATC inoculation using
a programmable pump. Such a longer survival was also the
case for one GBM patient in another study [51]. Steiner et
al. [50] found a better PFS in 23 GBM treated patients (40
weeks) in comparison with a control group of 87 patients
(26 weeks). These authors demonstrated a benefit in terms of
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OS (100 versus 49 weeks), 1-year survival (91% versus 45%),
2-year survival (39% versus 11%), and even 3-year survival
(4% versus 0%).
3.2. Active Immunotherapy Using Dendritic Cells. Vaccina-
tion with DC has been the most widely studied option: 19
studies (Table 4) [54–72], 11 phase I trials [55, 56, 59–61, 63,
64, 66, 67, 70, 71], 5 phase I/II trials [57, 62, 65, 69, 72], one
phase II trial [68], and two case reports [54, 58] including 313
patients. The antigen sources were varied: tumour lysates,
peptides eluded from ATC, defined peptides, mRNA derived
from ATC, and whole ATC in 10, 4, 1, 1, and 4 studies,
respectively. For vaccinations using ATC, the ATC were fused
or incubated with DC. Defined peptides were derived from
EGFRvIII [70], which appears to be a particularly interesting
target as its expression is frequent in GBM [13] and specific
of malignant cells.
In most studies, DC were prepared using a standard
method, that is, from peripheral monocytes cultivated in
the presence of GM-CSF and IL4. In six studies, they were
matured using diﬀerent cocktails with IL1β, TNFα, PGE2,
or IFNγ [57, 61, 63, 71, 72]. In one case, a TLR agonist
(OK432) was used [65]. Vaccines were injected intradermally
or subcutaneously. In one study, some patients also received
intracerebral injections [57]. In one, the vaccination was
combined with injections of recombinant IL12 [55]. The
number of cells injected ranged from 106 and 1010. The
number of injections and the frequency of the injections were
also highly variable.
Tolerance appeared to be acceptable with only one grade
IV neurotoxicity (stupor) event being reported for all of these
studies [65]. This patient with stupor had a large residual
tumour and a perilesional edema probably induced by
vaccination.Most of the toxic eﬀects were grade II (headache,
seizure, flu-like syndrome). A peripheral immune response
(demonstrated by in vitro tests or DTH) was observed in
more than half of patients. For the twenty-four patients who
relapsed after vaccination and had an analysable tumour,
lymphocyte infiltrations, particularly CD8 cells, were found
in 15 patients.
The radiological response was described in 10 studies
with 6CR (4GBM), 11 PR (5GBM), 7 MR (6GBM), and
27 SD (14GBM) among the 130 patients. Thirteen stud-
ies have reported a beneficial eﬀect in terms of survival
compared with historical cohorts or nonrandomized control
groups [56, 57, 59, 61, 62, 64, 65, 67–72]. Two studies were
unable to find any correlation between induced peripheral
immune response and clinical response [64, 72]. From
the largest cohort of patients reported (34GBM), Wheeler
et al. showed however that responders presented a global
increase of IFNγ synthesis (before versus after vaccination
using in vitro PBMC stimulation) compared with non-
responders. In addition, this study showed that responders
to vaccination exhibited a better response to chemotherapy
delivered in a second phase [68]. In their study, Liau et
al. [64] had four patients with increased intratumoural
infiltration by lymphocytes who had been vaccinated at a
time when the tumour was minimal. This T-cell infiltration
was correlated with decreased intratumour TGFβ and with
better survival. The opposite was observed for three other
patients without T-cell infiltration (vaccination in presence
of a major tumour, OS < 12 months, and strong presence
of intratumour TGFβ at relapse). One study showed that
patients vaccinated with mature DC had better survival
than those vaccinated with immature DC and that conjoint
administration of DC in the peripheral blood and intracra-
nially gave a superior response than peripheral injection
alone [65].
Summarizing, active immunotherapy appears to have a
beneficial eﬀect in some patients, particularly those with a
small tumour, without major toxicity. Both clinical trials
using ATC and DC demonstrate induced immune responses
(detected by DTH, tumour infiltration and/or anti-tumour
responses of PBMC) and some clinical responses. Once
again, due to the large variability of protocols tested in these
trials, that is, the source of ATC, the type of DC used, the
cell number injected, the number of injection, the type of
adjuvants, it is almost impossible to recommend a particular
approach. One can just point out that for DC, no dose-
related toxicity or eﬃcacy has been demonstrated [64]. In
addition, it seems better to favour mature DC compared to
immature DC.
4. Discussion
There were 76 objective responses (18CR and 58 PR) in
the 396 HGG patients described in the trials reported
in this paper. Forty-nine and 27 responses were reported
for adoptive and active immunotherapy, given objective
responses rates of 23% and 15% respectively. Only patients
with residual disease at the time of the vaccination can
be evaluated for CR or PR; patients who undergo a gross
total resection can only achieve stable disease as their best
radiographic outcome. For other solid tumours, similar cri-
teria based on radiological tumour measurements (RECIST-
based criteria) are used. Using these criteria, a 3.3% overall
objective response rate was reported for 1306 patients with
diﬀerent metastatic cancer vaccinated with peptides, pox
viruses, tumour cells, or dendritic cells [73]. Higher response
rate seems therefore to be observed for HGG. However,
one must emphasize that some trials reported in this paper
do not specify the exact criteria to define a PR and/or the
duration of the response. To achieve a CR or PR according
to Macdonald criteria, the most widely used criteria for
assessing responses to therapy in HGG, the radiological
response must be sustained for at least 4 weeks. Furthermore,
clinical assessment and corticoid dose must also be taken
into account. Few reports are currently evaluated following
these criteria, which renders diﬃcult comparisons between
trials, but could also lead to an optimistic interpretation
of some of them explaining the very high percentage of
responses. If clinical response has to be evaluated following
an immunotherapy protocol, one should advise to use the
Macdonald criteria, in particular the last recommendations
issued from the international neuro-oncology working group
that take into account some limitations of these criteria [74].
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Table 4: Active immunotherapy in high grade gliomas using dendritic cells (DCs)∗.
References
Type of
trial
Patients Antigen source
DC
maturation
Administration Immune response Clinical responses
[54]
Case
report
N = 1 recurrent
GBM
Acid eluted
peptides from
allogenic GBM
none ID (3 injections) TI T cells No survival benefit
[55] Phase I
N = 8 progressive
HGG
5 GBM, 2 AA, 1
AO after RT and/or
CT
Fusion of ATC
with DC
none
ID (1 to 7
injections)
Increased CD56 in
PBL (4/5)
ATR PBMC (6/6)
(IFNγ ELISA)
1MR, 4SD (GBM)
2SD (AA, AO)
[56] Phase I
N = 9 newly
diagnosed
HGG: 7GBM,
2AA after RT
Antigens eluted
from ATC
none ID (3 injections)
ATR PBMC (4/7)
(lytic activity)
TI CD4, CD8,
CD45RO cells
(2/4)
Median survival
after IT:
455 versus 257 days
(GBM)
[57] Phase I/II
N = 10 HGG
7GBM after RT,
3 recurrent GIII
ATC lysates+
KLH
none
ID and/or IC (1 to
10 injections)
DTH (3/6)
Increased CD56
(5/5); CD8, CD16,
CD19 (4/5) in PBL
ATR PBMC (2/5)
(IFNγ ELISPOT)
TI CD4, CD8 cells
(2/2)
2 MR, 2SD (GBM),
2SD (GIII)
OS > 200 weeks
(N = 2 ID+ IC;
N = 1 ID)
[58]
Case
report
N = 1 recurrent
GIII
ATC lysates none ID (6 injections)
DTH after 2nd
vaccination
CR maintained 2
years after IT
[59] Phase I
N = 14 HGG
1GBM, 1AA,
9 recurrent GBM,
3 recurrent AA
ATC lysates none SC (3 injections)
Increased IFNγ
RNA in PBMC
(6/10)
ATR T cells (4/9)
(HER-2, gp100,
MAGE-1
tetramers)
TI CD8, CD45RO
cells (3/6)
Median survival
after IT:
133 versus 30 weeks
(8 recurrent GBM)
[60] Phase I
N = 7 relapsed
brain tumours
2GBM, 1AA, 4
others Age: < 25
years
ATC RNA none
ID (3 to 5
injections)
No ATR PBMC
(0/3) (IFNγ
ELISA)
1 PR (1XA)
4 SD (1AA, 3 others)
[61] Phase I
N = 12 recurrent
HGG 11GBM, 1
PXA
ATC lysates
IL1β, TNFα,
and PGE2
ID (2 to 7
injections)
DTH after 2
vaccinations (6/8)
DTH after 5
vaccinations (7/8)
1 PR, 1 SD,1 CR
(GBM)
1CR (PXA) Median
OS: 10.5 months
36-month OS: 17%
[62] Phase I/II
N = 25 newly
diagnosed GBM
after RT Vaccine
alone (N = 12)
Vaccine and
chemotherapy
(N = 13)
ATC lysates or
peptide elutions
none ID (3 injections)
Vaccine alone: ATR
PBMC (4/11)
Vaccine and
chemotherapy:
ATR PBMC (4/13)
(lytic activity and
IFNγ Q-PCR)
Vaccine or
chemotherapy alone:
2-year survival: 8%
Vaccine and
chemotherapy: 3 PR -
2-year survival: 42%
[63] Phase I
N = 15 recurrent
HGG 6GBM,
7AA, 2 OAA
Fusion of ATC
with DC
TNFα ID (3 injections)
DTH (15/15)
ATR PBL (2/8)
(lytic activity)
1 SD (GBM), 3 PR,
1 MR (AA)1 PR, 1SD
(AOA)
[64] Phase I
N = 12GBM 7
newly diagnosed
GBM 5 recurrent
GBM
Acid elution
from ATC
none ID (3 injections)
ATR peripheral T
cells (6/12) (lytic
activity)
TI CD8 CD45RO
cells (4/8)
1 PR
Median OS: 23.4
versus 18.3 months
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Table 4: Continued.
References
Type of
trial
Patients Antigen source
DC
maturation
Administration Immune response Clinical responses
[65] Phase I/II
N = 24 recurrent
HGG 18GBM, 6
GIII after
RT+nitrosourea
ATC+ KLH
none or
OK432
ID (immature or
matured DC) +/−
IC (immature DC)
(1 to 10 injections)
DTH (8/17)
ATR PBMC
(7/16)(IFNγ
ELISPOT)
1PR, 3MR, 6SD
(GBM)
4SD (GIII) Median
OS: 480 versus 400
days Longer survival
if DC maturation or
IC injection
[66]
Phase I
N = 2HGG 1
recurrent GBM, 1
recurrent AA
after total resection
Irradiated ATC
Fibroblast
transduced
TGF/IL4
ID (2 injections)
ATR PBMC (1/1)
(EphA2 ELISPOT)
2 PR
N = 5HGG 5
newly diagnosed
GBM after total
resection+RT
ATC lysates
Mixture of
TGF/IL4
transduced
fibroblasts
with DC
(IFNγ, IL1β
and TNFα)
ID (2 injections) No response No response
[67] Phase I
N = 139GBM (2
recurrent),
4 AA (3 recurrent)
inactivated ATC none
ID (2 to 13
injections)
TI CD8 CD45RO
T cells (3/3)
12-month survival:
46%
18-month survival
or more: 23%
[68] Phase II
N = 34 GBM 23
recurrent 11 newly
diagnosed
ATC lysates none
ID (3 to 4
injections)
ATR PBMC
(17/34) (IFNγ
PCR)
3 CR, 1 PR
Median survival
after IT: 642 days
versus 430 days
[69] Phase I/II
N = 56 recurrent
GBM
ATC lysates
IL1β, TNFα
and PGE2
ID (3 to 9
injections +/−
ATC lysates)
DTH (9/21 at
diagnostic, 2/12
after vaccination)
Median OS: 9.6
months
[70] Phase I
N = 12 newly
diagnosed GBM
EGFRvIII
antigen + KLH
None ID (3 injections)
DTH EGFRvIII
(5/9)
DTH KLH (9/9)
ATR PBMC
(10/12)
(EGFRvIII-
induced
proliferation)
Median OS: 22.8
months
[71] Phase I
N = 45 children
HGG 23GBM,
5AA, 1 OAO, 16
other HGG
ATC lysates +
imiquimod
IL1β and
TNFα
ID (2 to 7
injections) +/−
ATC lysates boosts
All HGG: Median
OS: 13.5 months
GBM alone: Median
OS: 12.2 months
[72] Phase I/II
N = 8 newly
diagnosed GBM
(Stupp protocol)
ATC lysates
IL1β, TNFα,
and PGE2
ID (4 injections+
ATC lysates)
DTH (2/5)
Increased
CD8/CD25 in PBL
(6/7) ATR PBMC
(5/8) (IFNγ
ELISPOT)
Median OS: 24
months
∗: Abbreviations used in this table: see Table 1 to Table 3; KLH: keyhole limpet haemocyanin; PXA: pleomorphic xanthoastrocytoma; XA: xanthoastrocytoma.
The interaction between injected or induced immune
cells and tumour cells can lead to an equilibrium rather
than a destruction. Objective criteria based on changes in
the tumour masses may therefore not be well adapted to
assess this type of response. That is why survival is often
regarded as a better endpoint after immunotherapy. Several
studies reported in this paper have shown better survival for
patients treated with immunotherapy compared to patients
from historical cohorts or nonrandomized groups. All are
phase I/II trials, with a limited number of patients, which
must lead to a cautious interpretation. Lower tumour grade,
extent of resection, younger age, good performance status,
mutation of IDH1, as well as an intact neurological function
are recognised as favourable prognostic factors for HGG
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[75]. These factors should therefore be taken into account
for the survival analysis. This implies the implementation of
trials with higher numbers of patients and/or more selected
patients to lead to more conclusive data about the impact of
immunotherapy for HGG and GBM patients.
The immune therapy was in these trials well tolerated,
with few grade III/IV adverse events. Cerebral oedemas were
often detected in active immunotherapy using eﬀector cells
directly infused in the tumour site. However this side eﬀect
is diﬃcult to separate from oedema usually observed after
surgery. Alternatively, IL2 and GM-CSF used as adjuvant,
might lead to vascular perturbations leading in edema
formation. Therefore, anMRI before this type of treatment is
necessary to distinguish the increased cerebral edema due to
surgery from immunotherapy. The lack of other major side
eﬀects could be explained by the selectivity of the treatment
aiming at destroying specifically tumour cells. Alternative
explanations could be the relative ineﬃcacy of the treatment
or the frequently use of steroids in glioma that could
prevent some major side eﬀects. Up to now, major toxicity
has not been reported, except for one patient with bulky
residual tumour, for whom an overwhelming peritumoural
inflammatory reaction was observed, after injection of DCs
[61]. Phase III will help to validate the positive impact on
survival, without severe adverse event.
Treatment for newlydiagnosed GBM begins with surgery
when feasible, followed by focal radiotherapy (RT). For
patients up to 70 years, the current standard of care com-
prises also a temozolomide (TMZ) chemotherapy during
and after RT. At recurrence, repeat surgery, as well as
new lines of chemotherapy like nitrosourea or bevacizumab
(+/− irinotecan) may prolong survival in some patients.
Despite this multimodal treatment, mean overall survival
remains below 16 months [76]. Most studies reported in this
paper began while TMZ was not included in the standard
care, allowing the choice of immunotherapy immediately
after RT in newlydiagnosed patients. In some patients,
TMZ has marginal activity, if any, and MGMT status is a
strong predictive factor of response to TMZ [77]. These
patients should therefore benefit from alternative strategies,
like immunotherapy. Before this, the best technique for
MGMT analysis has to be assessed [78]. Another solution
is to add immunotherapy to the standard treatment, as
recently reported for 8 patients for whom DC injections
were performed between the end of the radio/chemotherapy
and the beginning of the adjuvant chemotherapy [72]. This
is based on the hypothesis that combination of treatments
could increase the tumour-specific response, as it has been
observed in animal models. RT could kill tumour cell by
apoptosis, favouring cross-presentation by APC, and it has
been shown that it upregulates the expression of MHC
molecules by tumour cells favouring their killing by CTL
[79–81]. TMZ could decrease the number of regulatory T
cells; also this eﬀect was only observed with a low-dose
metronomic regimen in a SC-implanted rat glioma model
[82]. CCL2 is produced by glioma tumour cells and has both
direct and indirect inhibitory eﬀects, among which attraction
of T reg cells. As TMZ can reduce CCL2 secretion by glioma
tumour cells, this could augment indirectly the eﬃcacy of
immunotherapy [83, 84]. Currently, most of the proposed
immunotherapy trials for HGG required that patients are
operated on, either to perform direct intracranial injection,
or to get tumour as source of tumour antigens. This induces
a limitation in the number of patients who can be enrolled
in this type of trial, particularly at the time of recurrence
(less than 10% have a second surgery in the study of
Bauchet et al. on 952GBM patients [76]). Another potential
limitation comes from the corticosteroids given to patients
to reduce tumour-associated oedema. Dexamethasone, fre-
quently taken by patients before and sometimes after surgery
induces a deep decrease in peripheral lymphocytes, as well as
an increase of abnormal circulating monocytes characterised
by the phenotype CD14+/HLA-DR low/neg [85]. This could
prevent the obtaining of large number of eﬀector cells in
some adoptive approaches and therefore decrease the treat-
ment eﬃcacy, although the impact of corticosteroids is not
clear for the reported studies. Furthermore CD14+/HLA-
DR low/neg monocytes are unable to fully diﬀerentiate into
mature DC, which can be a problem for vaccination with DC.
That is why some trials are restricted to patients oﬀ steroids
at the time of leukapheresis and during vaccination.
Up to now, the best results for patients with metastatic
melanoma have been obtained with adoptive therapy
involving lymphodepletion followed by the intravenous
injection of exvivo expanded TIL plus IL2. The addition
of the lymphodepletion preparative regimen consisting in
a chemotherapy (cyclophosphamide and fludarabine) and
whole body irradiation resulted in objective response rates
of 52% and 72% in two trials with both 25 patients, with
increased survival compared to patients who received T
cells without lymphodepletion. One of the key improve-
ments is the persistence of infused cells, which is highly
associated with objective response. Lymphodepletion could
act by eliminating competition for homeostatic cytokines,
in particular IL15, for which high levels can be detected
only after treatment. Other factors, like elimination of T reg
cells could also play major roles [86]. In case of residual
tumour after surgery, adoptive cell therapy could therefore
be an option for HGG, but it has to be refined in order to
increase eﬃcacy. The direct intracerebral delivery by infusion
in the tumour site at the time of surgery or by the use of
catheter/reservoir systems is often chosen in immunotherapy
using LAK and CTL cells. Indeed, this particular route
bypasses the finely regulated migration through the BBB and
therefore allows to have high number of eﬀector cells at the
tumour site. Data comparing with the same cells peripheral
and local injection are lacking, but clinical results are also
observed after intravenous injection. Standard in vitro tests,
such as phenotyping of eﬀector cells or killing assays against
tumour cells, should help to predict the treatment eﬃciency
on a particular patient. However, the phenotype of the
eﬀector cells used in the diﬀerent clinical trials with adoptive
therapies varies between patients and has no clear impact
on the clinical outcome that is, the presence of T-LAK
(CD3+) and LAK cells (CD3− CD56+) in LAK trials or the
ratio of CD4/8 cells in CTL trials. Moreover, most of the
studies using LAK and CTL cells could not correlate the
high cytotoxicity activity of the eﬀector cells observed in vitro
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against autologous tumour cells and the in vivo eﬃciency of
the treatment. This highlights the need to integrate the recent
advances in the field in order to improve the quality of the
injected cells. As the killing activity of LAK is not specific,
it seems better to use CTL. CTL can be expanded from
TIL repeatedly stimulated in vitro. This technique works
very well for melanoma, a tumour wellknown to induce
significant numbers of CTL during the natural course of the
disease. Though Quattrocchi et al., in the only trial using
this approach, expanded up to 3 × 109 lymphocytes from
tumours [35] it could be less adapted for glioma patients.
Another common source of CTL is PBMC from the patient.
Up to now, published studies have used autologous tumour
cells as antigenic stimulations, which can lead to polyclonal
expansion of specific CD8 and CD4 cells. Over the last
decades, significant progress in active immunotherapy has
been achieved in melanoma patients owing to the discovery
of well-defined tumour antigens expressed on melanoma
cells. As several glioma-associated antigens (GAAs) are
now known, it becomes possible to expand CD8+ T cells
against these GAA, giving the possibility to treat patient
even when tumour cells are not available, but also allowing
genetic modifications of the autologous lymphocytes [87].
As persistence of cells in vivo is a major point for the
success of adoptive immunotherapy, it is interesting to note
that persistence of eﬀector cells at the site of the tumour
was often transient as observed on biopsies or tumour
samples analysed after relapse in the reported studies. In
the addition to improve the injected cells, working on this
point could therefore lead to great improvements. Instead of
proposing heavy treatments inducing lymphodepletion, the
use of alternative cytokines to IL2, like IL15 could be tested as
well as the combination of an active vaccination. In an animal
model, the concomitant adoptive transfer of T cells and a
vaccination improves substantially the anti-tumour eﬃcacy
of the treatment [88]. It is likely that all these developments
will soon benefit to adoptive T-cell therapy against malignant
gliomas.
Most studies suggest that cancer vaccine could have the
most benefit in state of low tumour burden. This is also
observed in a series of 56 recurrent GBM patients vaccinated
with DC. Total resection before vaccination was the only
predictor of a better survival [69]. In contrast to adoptive
immunotherapy, for which administered eﬀector cells can
lead to a direct lysis of tumour cells, active immunotherapy
requires the initiation and development of an immune
reaction. Due to the risk of a rapid regrowth of the tumour
before the development of an eﬀective antitumoral reaction
in case of residual disease, one may advice treatment with
active immunotherapy only after maximal tumour resection.
Vaccination strategy can consist of inoculation of inac-
tivated autologous tumour cells. The first limitation step of
the approach is the culture of the tumour cells. It is not
always possible to establish primary cell lines frommalignant
gliomas. In the study of Parney, on 116 malignant gliomas,
culture was successful in 61% of cases [51]. In some cases
in vitro growth is not suﬃcient to allow vaccination. The
delay between the beginning of the culture and the time when
vaccine preparation is available can be very long. Median
expansion times range between 4.5 and 30 weeks [47, 50,
51, 53], which explain that some patients may progress
before receiving the vaccine. One additional limitation is
the possibility that the immunologic phenotype of glioma
cells might change after passaging in vitro (Anderson, 2002)
[89], which could decreases the eﬃcacy of the vaccine. Very
often, cells are injected with adjuvants like IL2 or GM-
CSF are modified to express costimulatory molecules or
cytokines, or are infected with virus in order to increase
their immunogenicity. The way all these potential adjuvants
act is poorly understood and their real impact is debate.
For example, the use of combined GM-CSF is supported
by numerous preclinical studies, in gliomas and in other
cancers [90–92]. However, two recent randomized trials in
melanoma patients showed that GM-CSF could be harmful
as immune adjuvant. In the first study, patients received
allogeneic tumour cells and BCG, with or without GM-
CSF. A diminished DTH response as well as an increase in
early deaths was observed in the GM-CSF arms [93]. In
the second study, 12 MHC class I-restricted and one HLA-
DR-restricted tetanus peptides were injected with or without
GM-CSF. CD8+ and CD4+ T-cell response rates to the
injected peptides were higher without GM-CSF [94]. Eﬀects
could be diﬀerent according to the route of administration
and the doses [45]. A possible mechanism by which GM-CSF
could interfere is the induction and activation of myeloid-
derived suppressor cells [95]. This highlights well that
manipulating the immune system can induce stimulation as
well as suppression. All the diﬃculty of immunotherapy lies
in finding the good equilibrium between both.
Most of vaccination protocols for HGG patients have
used DC, the most potent APC. This reflects the popularity
of this vaccine approach: up to now, more than 3000 patients
suﬀering from varied cancers, enrolled in more than 200
trials have received DC (http://www.mmri.mater.org.au/).
Many recent reviews have focused on the use of DC as
cancer vaccine [96–98], and in particular for malignant
gliomas [99–101]. Many options are available about the
way to prepare DC, to load them with tumour antigens,
to inject them. Some processes used in the protocols for
HGG patients require to have autologous tumour cells, to
elute peptides, or to fuse them with DC. This implies large
cultures of tumour cells and thus the problems already
discussed. To overcome this issue, glioma-cell lysate are used
in a number of trials. This has the advantage of providing
a panel of personalised class I and class II peptides, like
with autologous tumour cells. There is however a theoretical
risk of autoimmune encephalomyelitis, due to the frequent
presence of nontumour glial cells in the tumour. Though up
to now such side eﬀects have not been reported, one can fear
that in the case of higher eﬃcacy of immunotherapy it may
happen. DC can be loaded with synthetic tumour antigens
like peptides (short or long), proteins or transfected with
encoding antigen nucleic acids. In one published study, DC
were pulsed with EGFRvIII peptides [70] and in an ongoing
study, DC are loaded with 4 peptides derived from EphA2,
IL-13Rα2, YKL-40, and GP100 [18]. The use of defined
TAA reduces the risk of autoimmunity (if TAAs are specific
to tumour cells), but it implies the previous selection of
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patient according to their MHC haplotype if using peptides
and sometimes patients are also selected according to the
expression of the tumour antigens by the tumour. Currently,
a universally expressed glioma TAA does not exist, limiting
the usefulness of this approach to patients whose tumour
expresses the selected TAA. Furthermore, with the use of a
limited number of tumour antigens, there is a theoretically
greater risk of an immune escape due to clonal expansion of
antigen-loss variants. Among the improvement expected in
the loading of DC, the use of antigens expressed by tumour
stem cells could be a promising perspective, due to the major
role these cells may play in the regrowth of tumour after
treatment [102, 103].
About the best way to generate DC in vitro, specialists
consider that mature DCs (mDC) are superior to immature
DCs (imDC) [98]. They can migrate in higher rate to
the draining lymph nodes after peripheral injection, they
upregulate several costimulatory molecules and can produce
diﬀerent cytokines. Improving the maturation protocol, in
order to have the “perfect” DC remains a big challenge in
the field. Most published clinical trials in HGG have used
imDC or DC matured with pro-inflammatory cytokines. An
interesting alternative to mature DC is the use of Toll-like
receptor (TLR) ligands, which can mimic bacterial or viral
infections, triggering a process of maturation in DC. In the
study of Yamanaka et al., patients received either imDCs or
DCsmatured withOK432, a streptococcal preparation acting
notably through the activation of TLR4. Patients vaccinated
with mDC had longer survival than those vaccinated with
imDC [65]. Van Gool et al. reported an improvement in
PFS curves between HGG whose skins were pretreated with
imiquimod (which binds TLR7) before the injection of DC
matured with TNFα and IL1β and patients receiving only DC
matured with TNFα, IL1β, and PGE2 [99]. The maturation
cocktail designed by Mailliard and colleague (poly I:C, IFNα,
TNFα, IL1β and IFNγ) allows the generation of fully mature
DC, with high migratory responsiveness to lymphoid organ
chemokines and an ability to produce significant levels of
IL12p70 after CD40 ligation (which mimics the interaction
between DC and CD40L-activated cells in lymph nodes)
[104]. In a model of tumour-bearing mice such so-called
α-type-1 polarized DCs, pulsed with peptide antigens can
migrate into draining lymph nodes after SC injection and
induce antigen-specific CTL, allowing a prolong survival.
The secretion of CXCL10 by these DC seems to play a major
role in the induction of specific CTL and their homing to
the brain [105]. As the eﬃcacy of type-1 α-DC loaded with
glioma-associated antigen epitopes, in combination with the
administration of poly-ICLC, is currently tested in recurrent
malignant gliomas [18], the translation (or not) of these
promising results into the clinic will be known soon.
The relevance of intravenous DC injection has never
been tested for HGG patients. It is worth noting that the
only autologous cellular immunotherapy approved by the
US FDA is based on the intravenous administration of
PBMC cultured with recombinant PAP-GM-CSF for the
treatment of metastatic prostate cancer [106]. In most of
the studies reported in this paper, DC were injected in
the skin. As priming of T cells within the cervical lymph
is important to induce eﬀector T cells with the ability to
home in to the central nervous system, injection of DC in
regions allowing them to reach these nodes appears to be a
good option. Direct intranodal injection, under echographic
guidance is also feasible and allows more DC to reach the
nodes. However, following intranodal injection, DC are not
always correctly injected into the nodes [107, 108] and as
limited numbers of DC in the draining lymph nodes are
suﬃcient to induce a specific immunologic response [109],
intradermal injections appear as the best compromise. In
their study, Yamanaka et al. showed that patients receiving
both intratumoral and intradermal DC injections had longer
overall survival than those receiving only intradermal DC
[65]. The usefulness of this combination has recently been
confirmed in animal models: the addition of intratumour
injection to SC injections leading to an increase of CD8+ T
cells in the tumour and an increase in survival [105, 110].
Intratumoural DC activity could be due to intratumour
secretion of cytokines and chemokines (depending on the
type of DC injected) and/or migration of DC to draining
lymph nodes. A better understanding of this mechanism
should therefore lead to considering this option for future
trials.
Whatever the immunotherapy approach, one funda-
mental element to take into consideration is the corrupted
tumour microenvironment which favors tumour develop-
ment. Diﬀerent mechanisms developed by glioma cells can
suppress anti-tumour immune responses. Several defects at
the systemic level have been reported in glioma patients
such as decreased T-cell responsiveness [111, 112], increased
circulating regulatory T cells [113, 114], and defective
monocytes and DC functions [115–117]. Various factors
produced by glioma cells might contribute to these defects
such as TGFβ, PGE2, and IL10 [118–123].
Beside these systemic eﬀects, glioma cells develop several
molecular strategies to inhibit directly the immune cell
eﬀectors at the tumour site. Several intracellular, membrane
and soluble molecules have been described as taking part
in this phenomenon such as CD70 [124, 125], FasL [126–
128], gangliosides [125], HLA-G [129], PDL-1 [130–132],
IDO [132–134], and TGFβ1-3 [135]. We have recently
described the involvement of TGFβ2, IDO, and PDL-1 on
GBM immunosuppressive properties on T-cell functions
in a tumour-specific T-cell model [132]. Diﬀerent groups
have also focused on immunosuppressive cells that are
recruited at the site of the tumour. Indeed, tumour immune-
derivation involved a particular chemokine profile that could
specifically induce the recruitment immunosuppressive cells
such as T reg and myeloid-derived suppressor cells (MSDC).
Glioma-infiltrating microglia/macrophages (GIM) represent
the largest population infiltrating human glioma with
around a third of the cells present in the tumour mass [114].
GIM are poor T-cell activators due to lower expression levels
of molecules such as HLA class II or costimulatory CD80 and
CD86 molecules [114]. Furthermore, GIM secrete factors
that support the tumour invasion and proliferation [18]. As
described systemically, T cells are also present at the tumour
site [114, 136, 137], although their presence seems to have
no impact in patient prognosis. MDSC are a heterogeneous
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population of cells that can suppress T-cell responses [138].
One recent study performed in a rat model has shown
an infiltration of such cells following immunization with
tumour antigens [139]. These cells could therefore play a
major role in gliomas.
A better eﬃcacy could certainly associate optimized stan-
dard immunotherapy protocols with treatments designed
to hamper this immunomodulation. The early results using
immunomodulator molecules have been encouraging (as an
example CTLA4 blockade in melanoma patients [140]) and
one trial in melanomas recently demonstrated the potential
interest of combination of CTLA4 blockade with a DC
vaccine [141]. Diﬀerent strategies are currently under study
to decrease the deleterious eﬀect of Treg as injection of low-
dose cyclophosphamide (metronomic cyclophosphamide)
[142], or injection of CD25 (high) targeting immunotoxin
(denileukin diftitox). This latter approach has also been
tested in association with DC vaccination [143]. Molecules
designed to inhibit the action of TGFβ, IDO, and PD1
are also being tested clinically. Preclinical studies in glioma
models have shown the interest to combine vaccination with
inhibition of TGFβ [144] or depletion of Treg [145].
In conclusion, immunotherapy can be considered as a
potential new interesting weapon for treatment of patients
with HGG and one should expect many improvements of
this type of approach over the next years. However, there
is a need for well-designed trials with higher numbers and
more homogenous patients, taking into account the current
recognized prognostic or predictive factors like and leading
to phase III randomized studies.
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